PI Health Sciences Financial Overview
PI Health Sciences: Initial development spend reflecting in the financials...
Integration of CRO-CDMO-API platforms underway
Fig in Rs. Million
Revenue
65
Gross Margin
54%
Q3FY24 Ind AS Q3FY24
Proforma Adjustment Reported
1,207
1,273
51%
9MFY24
2,839
Ind AS
Proforma Adjustment
(405)
9MFY24
Reported
■ State-of-the-art research
centre in Hyderabad
2,434
62%
58%
Overheads
650
650
1,650
1,650
EBITDA
1
3
4
118
(351)
(233)
EBITDA as % of Revenue
0%
0%
4%
N.M.
9MFY24
Pi
Inspired by Science
■ CMO for RSM and KSM and
CRDO at Jaipur
■CRDO in Alabama, US
■ GMP Speciality API and
CDMO plant at Lodi, Italy
Aforesaid financials represent consolidated financials of PI Health Sciences
Ltd. including acquired businesses of Archimica S.p.A., Therachem Medilab,
PIHS Hyderabad etc.
■ Proforma EBITDA for 9MFY24, before development spend of ~Rs. 350 million,
works out to ~16%.
■ Inventory of Rs. 865 million reduced from Rs. 1,172 million as on 30-Sep-23.
■ Capex 9MFY24 of Rs. 1,008 million.
Few areas of integration activities
Strategic
■In-depth mapping of global CRDO-CDMO value chain
■ Areas of strategic focus and differentiation for PIHS
■ SAP integration across all sites
IT
■ Seamless and common platform for email, processes
■Integrated organisation structure
HR
■ Job bands and HR policies harmonisation
SCM
■ Procurement and logistics processes digitized
■S & OP procedures standardised
On path to build future growth engine for PIView entire presentation